Towards an AIDS vaccine: challenges and prospects |
| |
| Affiliation: | 1. Jacques Homsy is at the Cancer Research Institute, S-1280, School of Medicine, University of California, San Francisco, California 94143, USA;2. Kathelyn Steimer is with Chiron Corporation, Emeryville, California 94608, USA;3. Richard Kaslow is at the National Institutes of Health, Westwood Building, Room 739, Bethesda, Maryland 20892, USA;1. World Health Organization, Geneva 1202, Switzerland;2. Ministry of Health, Brasília, Brazil;1. The University of North Carolina at Chapel Hill, Department of Social Medicine, Chapel Hill, NC 27599, USA;1. Institut Pasteur, Paris, France;2. Clinical Sciences and Operations, Sanofi, Chengdu, China;3. Sanofi, Swiftwater, PA, USA;4. MRC Antibody Immunity Research Unit, School of Pathology, University of the Witwatersrand, Johannesburg, South Africa;5. National Institute for Communicable Diseases of the National Health Laboratory Services, Johannesburg, South Africa;6. Sanofi, Waltham, MA, USA;7. Centre for the AIDS Programme of Research in South Africa, University of Kwazulu-Natal, Durban, South Africa;8. Sanofi, Reading, UK |
| |
| Abstract: | ![]()
Since the human immunodeficiency virus (HIV) started its spread through the human population, the AIDS epidemic has steadily increased on all continents unchecked by any therapeutic or preventive intervention, except for education. The search for an AIDS cure is facing great difficulties as HIV, a human retrovirus, is able to integrate and remain latent in the human genome for years. An effective vaccine thus remains the only foreseeable way to control and eventually eradicate AIDS. The unique pathogenicity and variability of HIV have raised new challenges in vaccine design, testing and evaluation. The status of the intense research efforts undertaken to solve these problems were assessed at a recent workshop on the AIDS vaccines. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
